Consistent <i>in vitro</i> activity of sulbactam-durlobactam against genetically diverse carbapenem-resistant <i>Acinetobacter baumannii</i> in a high-endemic Brazilian setting
ABSTRACT Carbapenem-resistant Acinetobacter baumannii (CRAb) causes high-mortality infections, with limited treatment options. We evaluated sulbactam-durlobactam activity against 94 isolates from Brazil. Durlobactam markedly reduced sulbactam MICs, restoring susceptibility in all CRAb. They belonged to seven STs, mainly ST730 and ST79. Despite genetic and phenotypic diversity, including distinct carbapenemase genes (particularly bla OXA-23-like ) and the presence of PBP3 mutations, activity remained consistent. These findings support sulbactam-durlobactam as an effective option against CRAb in this high-endemic setting.
Authors
- Jaqueline Becker Pinto
- Mariana Preussler Mott (ORCID: https://orcid.org/0000-0001-5130-9057)
- Juliana Caierão (ORCID: https://orcid.org/0000-0002-8776-8447)
- Patricia Orlandi Barth (ORCID: https://orcid.org/0000-0003-0763-1430)
- Luana Silva Dornelles
- Dariane Castro Pereira (ORCID: https://orcid.org/0000-0002-9119-6242)
- Afonso Luís Barth (ORCID: https://orcid.org/0000-0002-7969-3908)
- Gabriela da Silva Collar (ORCID: https://orcid.org/0000-0003-2819-0769)
- William Latosinski Matos
- Andreza Francisco Martins (ORCID: https://orcid.org/0000-0001-6227-1920)
- João Vitor Barboza Cardoso
- Júlia Cover Salvador
Institutions
- Universidade Federal do Rio Grande do Sul (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Hospital Nossa Senhora da Conceição (BR)
- Grupo Hospitalar Conceição (BR)
- Hospital de Clínicas (UY)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-06-12
- DOI
- https://doi.org/10.1128/aac.00109-26
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hospital de Clínicas de Porto Alegre